{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:55:20Z","timestamp":1792742120331,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is a highly prevalent and lethal malignancy worldwide, with its incidence steadily rising over recent decades. Conventional treatments, including chemotherapy, surgery, immunotherapy, Targeted Therapy and radiotherapy, offer limited therapeutic benefit. Chimeric antigen receptor (CAR)-based immunotherapy has emerged as a promising strategy for HCC, yet significant challenges remain. This study aims to provide a comprehensive overview of the current landscape and future prospects of CAR-based immunotherapy in HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>On September 30, 2025, we conducted a systematic literature search in the Web of Science Core Collection (WoSCC) and Scopus databases, targeting publications from 2016 to 2025. Full records and cited references were extracted and screened. Data-driven analyses and visualizations were performed using CiteSpace, Microsoft Excel 2019, VOSviewer, and R software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5,210 publications were included in the analysis. The number of studies in this field has increased sharply since 2019 and is projected to continue rising. China, particularly its universities, leads global research in this area. Most influential studies were concentrated around 2019. Research hotspots have shifted from traditional pharmacology toward gene regulation and the tumor microenvironment (TME). Collaboration networks among authors, countries, and institutions indicate a growing trend toward multidisciplinary cooperation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAR-based immunotherapy for HCC remains in its early stages of development. Future research should prioritize enhancing therapeutic efficacy and safety, fostering international collaboration, and promoting interdisciplinary approaches to improve clinical outcomes for HCC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1778197","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:54:20Z","timestamp":1776837260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Current progress and emerging trends of car-based immunotherapy for hepatocellular carcinoma: a data-driven atlas from multidatabase integration"],"prefix":"10.3389","volume":"17","author":[{"given":"Hao","family":"Ying","sequence":"first","affiliation":[{"name":"Department of Oncology, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutesof Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Oncology, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutesof Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijia","family":"Xuan","sequence":"additional","affiliation":[{"name":"Department of Oncology, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutesof Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"420\u2013","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019","volume":"8","author":"Kocarnik","year":"2021","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/516s1a","article-title":"Liver cancer","volume":"516","author":"Gravitz","year":"2014","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2017.0112","article-title":"Epidemiology of liver cancer in South Korea","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"a021535","DOI":"10.1101\/cshperspect.a021535","article-title":"Treatment of liver cancer","volume":"5","author":"Liu","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.07.018","article-title":"Heterogeneity of liver cancer and personalized therapy","volume":"379","author":"Li","year":"2015","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418965","article-title":"The current status and future of targeted-immune combination for hepatocellular carcinoma","volume":"15","author":"Hao","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108634\u2013","DOI":"10.1016\/j.pharmthera.2024.108634","article-title":"Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis","volume":"257","author":"Wang","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","article-title":"Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors","volume":"42","author":"Espinosa-Carrasco","year":"2024","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1431211","article-title":"Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy","volume":"15","author":"Du","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824208","article-title":"Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-19-0293","article-title":"Glypican-3\u2013specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e001875","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting glypican-3 in hepatocellular carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13045-017-0535-7","article-title":"Clinical trials of CAR-T cells in China","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2022.1434","article-title":"VOSviewer and bibliometrix","volume":"110","author":"Arruda","year":"2023","journal-title":"J Med Libr Assoc"},{"key":"B24","article-title":"CiteSpace II: Visualization and Knowledge Discovery in Bibliographic Databases. AMIA Annu Symp Proc. Washington, DC: American Medical Informatics Association","author":"Synnestvedt","year":"2005"},{"key":"B25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/s1470-2045(09)70171-8","article-title":"Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study","volume":"10","author":"Faivre","year":"2009","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13191","article-title":"Immune checkpoint blockade for the treatment of human hepatocellular carcinoma","volume":"48","author":"Nishida","year":"2018","journal-title":"Hepatol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.0143","article-title":"AKT inhibition in solid tumors with AKT1 mutations","volume":"35","author":"Hyman","year":"2017","journal-title":"JCO"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J Clin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut\u2013liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ejca.2011.12.021","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"48","author":"Llovet","year":"2012","journal-title":"Eur J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA A Cancer J Clin"},{"key":"B35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/nejmoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Ally","year":"2017","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216334","article-title":"The past, present, and future of liver cancer research in China","volume":"574","author":"Sun","year":"2023","journal-title":"Cancer Lett"},{"key":"B43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-024-01616-8","article-title":"Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China","volume":"17","author":"Du","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00967-4","article-title":"Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions","volume":"21","author":"Mak","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-025-02756-8","article-title":"Is cross-border transfer of China\u2019s human genetic data an impossible mission","volume":"144","author":"Chen","year":"2025","journal-title":"Hum Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01075-1","article-title":"Optimizing CAR T cell therapy for solid tumours: a clinical perspective","volume":"22","author":"Li","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.09.012","article-title":"Engineered T-cell therapy for hepatocellular carcinoma: the dawn of precision immunotherapy","volume":"84","author":"Hsu","year":"2026","journal-title":"J Hepatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103046","article-title":"CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation","volume":"141","author":"Elahi","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"200817\u2013","DOI":"10.1016\/j.omton.2024.200817","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma","volume":"32","author":"Zhou","year":"2024","journal-title":"Deleted J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01287-8","article-title":"GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma","volume":"45","author":"Sun","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20517\/2394-5079.2025.69","article-title":"Emerging potential of CAR-NK cell therapy for hepatocellular carcinoma: current advances and translational challenges","volume":"12","author":"Chu","year":"2026","journal-title":"Hepatoma Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12951-025-03424-9","article-title":"A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection","volume":"23","author":"Cheng","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat BioMed Eng"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B61","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.02.033","article-title":"Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances","volume":"368","author":"Zhang","year":"2024","journal-title":"J Control Release"},{"key":"B64","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2014","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2016","journal-title":"Cell Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266766","article-title":"Peptide binder to glypican-3 as a theranostic agent for hepatocellular carcinoma","volume":"65","author":"Lin","year":"2024","journal-title":"J Nucl Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4095\u2013","DOI":"10.1200\/jco.2023.41.16_suppl.4095","article-title":"Phase I trial of chimeric anti-GPC3 scFv-CD3\u03f5 engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma","volume":"41","author":"Zheng","year":"2023","journal-title":"JCO"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2543\u2013","DOI":"10.1200\/jco.2024.42.16_suppl.2543","article-title":"Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors","volume":"42","author":"Nakajima","year":"2024","journal-title":"JCO"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1180001","article-title":"Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107619","article-title":"The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells","volume":"212","author":"Sui","year":"2025","journal-title":"Pharmacol Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200859","article-title":"Targeting hepatocellular carcinoma heterogeneity with FAP and GPC3-specific tandem CAR-T cells","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1653452","article-title":"Asialoglycoprotein receptor 1: a multifaceted receptor in the liver and cardiovascular system","volume":"12","author":"Xiao","year":"2025","journal-title":"Front Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12672-025-02095-0","article-title":"Biological roles and clinical applications of EpCAM in HCC","volume":"16","author":"Liu","year":"2025","journal-title":"Discover Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-024-00752-1","article-title":"Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma","volume":"8","author":"Ye","year":"2024","journal-title":"NPJ Precis Onc"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-024-02353-z","article-title":"Transformers in single-cell omics: a review and new perspectives","volume":"21","author":"Sza\u0142ata","year":"2024","journal-title":"Nat Methods"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.03.002","article-title":"In silico off-target profiling for enhanced drug safety assessment","volume":"14","author":"Liu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","article-title":"Engineering switchable and programmable universal CARs for CAR T therapy","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.08.018","article-title":"TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity","volume":"32","author":"Dharani","year":"2024","journal-title":"Mol Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-020-00890-6","article-title":"Gene modification strategies for next-generation CAR T cells against solid cancers","volume":"13","author":"Tian","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:54:28Z","timestamp":1776837268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2026.1778197"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1778197","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1778197"}}